Panel Discussion: Discussing the Next-Generation of Novel Modalities to be Used for Enhanced Delivery & Broader Impact in CNS & Ophthalmic Indications
12:00 pm - Wednesday 3rd December 2025
- Addressing the critical challenge of achieving sufficient complement inhibitor exposure in the CNS, a major reason for past failures with peripherally acting drugs
- Exploring novel delivery modalities like gene therapy, shuttle technologies that are in early development, to unlock the therapeutic potential of complement inhibition neurodegenerative diseases
- Highlighting the significant appeal and ongoing development of gene therapies for chronic ophthalmic conditions driven by complement
